Clinical Trial Search

Primary: Mean Change From Baseline to 24 Weeks in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.5; 1.6; 1.6; 1.6 SSEs per week

Primary: Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment — 2.115; 0.859 CAEs in 52 weeks — p=<0.0001

Primary: Change From Baseline in CRT as Measured by SD-OCT on Day 29 — 44.0 μm

Primary: Clinical Validation of Biosensor Assays Used for Pathogen Identification and Antimicrobial Susceptibility Testing in Patients at Risk of Urinary Tract Infections. — 89…

Primary: Satisfying Sexual Event Monthly Change From Baseline at Final Visit — 0.8; 1.4; 1.6 number of events — p=0.0454

Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120

Primary: Freedom From Serious Adverse Event (SAE) at 30days — 22 participants

Primary: Overall Summary of Adverse Events (AEs) — 67.65; 47.06; 7.06; 0.59 Percentage of participants

Primary: Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52 — 1.6; 1.7; 1.2; 1.1 units on a scale

Primary: Fraction of Middle Ear (ME) Pressure Equilibrated (FGE) — 0.17; 0.24; 0.19; 0.23 ratio — p==0.93

Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561

Primary: Rate of Complete Remission — 25 patients

Primary: Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment — 1.804; 0.904 CAEs in 52 weeks — p=<0.0001

Primary: Percentage of Participants With a Disease Activity Score (DAS) Response at 78 Weeks Where DAS Response is Defined as a Reduction From Baseline in DAS 28-joint Count…

Primary: Area Under the Receiver Operating Curve (ROC) as a Measure of the Accuracy of the APACHE II and P-POSSUM Scoring Systems to Predict Mortality — 0.965; 0.989 probability…